Other biomarkers of inflammation are associated with greater risk of coronary disease (3), and U.S. guidelines recommend that high-sensitivity C-reactive protein can be measured to inform decisions on cardiovascular risk management in uncertain cases (31). This evidence concerns the gene CRP and coronary artery disorder.